Showing papers by "Angelo Branzi published in 1994"
TL;DR: It is suggested that brief and infrequent episodes of VT should not be considered, per se, an indication for antiarrhythmic treatment in patients with hypertrophic cardiomyopathy who were asymptomatic or had only mild symptoms at the time of their initial ambulatory ECG recording.
Abstract: congestive heart failure. Thetotal cardiac mortality ratewas 1.4%peryearinthepatients with VT (95%CI,0.4%to3.5%) and0.9%inthose without VT(95%CI,0.4%to2.0%; P=.43). Therelative risk ofcardiac death forpatients withVT was 1.4 compared withpatients without VT (95%CI,0.6to6.1). The sudden death ratewas 1.4%peryearinthepatients withVT (95%CI,0.4%to3.5%)and0.6%inthose without VT (95% CI,0.2%to1.5%; P=.24). Therelative risk ofsudden death forpatients withVT compared withthose without VT was 2.4 (95%CI,0.5to11.9). Ofthe151patients included inthestudy, 88(58%)remained asymptomatic andwere nottreated with cardioactive medications during follow-up. Ofthese 88patients, 20were inthegroupwithVT and68inthegroup without VT.Noneofthese patients died. Conclusions Ourresults showthat cardiac mortality islow inpatients withhypertrophic cardiomyopathy who are asymptomatic oronlymildly symptomatic andhavebrief and infrequent episodes ofVT on ambulatory ECG monitoring. Ourfindings also suggest that brief andinfrequent episodes ofVT should notbeconsidered, per se,an indication for antiarrhythmic treatmentinsuchpatients. (Circulation. 1994;90:2743-2747.)
188 citations
TL;DR: Both Heptest and heparin cofactor II affinity were significantly increased (P < 0.001) in a dose-dependent manner and the Xal was enhanced, though to a lesser extent, while systemic and local tolerance were always very good.
Abstract: Sixteen patients (5 female and 11 male, mean age 59.1 years) who had had an acute myocardial infarction within the previous 7 days, were enrolled in an open pharmacodynamic study. Patients were randomly allocated to two treatment groups and given a single subcutaneous dose of 100 or 200 mg of a new low-molecular-weight dermatan sulphate. The drug pharmacodynamic profile was determined 1, 2, 4, 6, 8, 12 and 24 h after administration. The following coagulation and fibrinolysis tests were performed: activated partial thromboplastin time, thrombin time, activated factor X inhibition, Heptest (global clotting time), heparin cofactor II affinity, functional and antigenic plasminogen activator inhibitor and fibrin plate assay. Both Heptest and heparin cofactor II affinity were significantly increased (P < 0.001) in a dose-dependent manner. The XaI was enhanced, though to a lesser extent. None of the other coagulation or fibrinolysis tests showed significant changes at either dose. Systemic and local tolerance were always very good.
9 citations